Annovis Bio, Inc. (ANVS) is a publicly traded Healthcare sector company. As of May 20, 2026, ANVS trades at $1.59 with a market cap of $71.03M and a P/E ratio of -1.41. ANVS moved -5.85% today. Year to date, ANVS is -46.85%; over the trailing twelve months it is -8.49%. Its 52-week range spans $1.11 to $10.54. Analyst consensus is buy with an average price target of $12.50. Rallies surfaces ANVS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
ANVS financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. ANVS recently traded at $1.59. Market cap is $71.03M. P/E ratio is -1.41. Revenue is $0.
| Metric | Value |
|---|---|
| Price | $1.59 |
| Market Cap | $71.03M |
| P/E Ratio | -1.41 |
| EPS | $-1.40 |
| Dividend Yield | 0.00% |
| 52-Week High | $10.54 |
| 52-Week Low | $1.11 |
| Volume | 727.16K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-28.85M |
| Gross Margin | 0.00% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0 | $-28.85M | $-1.40 |
| 2024 | $0 | $-24.59M | $-2.02 |
| 2023 | $0 | $-56.20M | $-6.23 |
| 2022 | $0 | $-25.33M | $-3.10 |
2 analysts cover ANVS: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $12.50.